Showing: 1 - 5 of 5 RESULTS

Rudy Giuliani taking hydroxychloroquine to fend off COVID-19 despite safety concerns

NEW YORK — Rudy Giuliani will apparently never get off the hydroxychloroquine train.

The ex-New York mayor told the New York Daily News on Wednesday that he’s taking the anti-malarial drug as a preventative measure against COVID-19 — even though U.S. regulators advise against it over concerns that the medication can cause serious side effects.

Giuliani, 76, stressed that he has tested negative for the virus several times in the past few days, but said his doctor recommended the hydroxychloroquine regimen since he spent considerable time last week with President Donald Trump and others who have since tested positive.

“All negative so far and no symptoms but I am taking hydroxychloroquine and zinc as a prophylactic,” said Giuliani, who’s these days best known as Trump’s combative personal lawyer. “A study in Italy showed exceptional results.”

Despite Giuliani’s claim that he’s not experiencing symptoms, a source familiar with the matter told The News that the ex-mayor was openly coughing while having dinner Tuesday night at Amata’s in Midtown.

“He really should be in quarantine,” the source said.

Giuliani did not outright deny the source’s observation.

“I am negative and I don’t think I coughed and I was 20 feet away from anyone and wore my mask when the waiter served me,” he said.

The Food and Drug Administration issued guidance in July advising doctors against prescribing hydroxychloroquine to any COVID-19 patients because the drug had not proved effective in treating or preventing the virus.

The FDA also said the drug could cause “abnormal heart rhythms,” especially in patients with preexisting heart or kidney conditions.

But Giuliani claimed the FDA guidance “was all political.”

“It’s a very effective early-stage cure per NYU, French, Italian, Chinese, Brazilian studies,” Giuliani said.

Like Giuliani, Trump has pushed hydroxychloroquine as a COVID-19 miracle cure for months.

Nonetheless, the president’s medical team did not prescribe the anti-malarial drug during his hospitalization at Walter Reed Medical Center this past weekend.

Giuliani traveled with Trump onboard Air Force One last week for his first debate against Joe Biden in Cleveland.

Hope Hicks, Chris Christie, Kayleigh McEnany, Stephen Miller and dozens of other White House staffers and associates of the president have also tested positive for COVID-19.

Giuliani told The News that he doesn’t believe he’s totally out of the woods yet.

“It’s been seven full days now so let’s hope,” he said. “I’ll take another test tomorrow or Friday.”

———

©2020 New York Daily News

Visit New York Daily News at www.nydailynews.com

Distributed by Tribune Content Agency, LLC.

Source Article

Study shows hydroxychloroquine did not prevent coronavirus in health care workers

A new study has found that hydroxychloroquine, the anti-malaria drug that President TrumpDonald John TrumpTrump signs bill averting shutdown after brief funding lapse Privacy, civil rights groups demand transparency from Amazon on election data breaches Facebook takes down Trump campaign ads tying refugees to coronavirus MORE said he took to ward off coronavirus, did not prevent COVID-19 among health care workers.

The study, published Wednesday in the journal JAMA Internal Medicine, was conducted at two urban hospitals between April 9-July 13 among 132 full-time health care workers exposed to the virus. However, the trial was ended early.

Some participants were given 600 mg daily doses of hydroxychloroquine while others were given a placebo for eight weeks.

“There was no significant difference in infection rates in participants randomized to receive hydroxychloroquine compared with placebo,” the researchers from the University of Pennsylvania wrote.

Four of the 64 healthcare workers who were randomly given hydroxychloroquine ended up testing positive for COVID-19 and four of the 61 healthcare workers who were given a placebo tested positive.

Among those eight participants who tested positive, six developed viral symptoms. None required hospitalization and they all clinically recovered from the illness, according to the study.

“As such, we cannot recommend the routine use of hydroxychloroquine among (health care workers) to prevent COVID-19,” researchers concluded.

The findings of the newly released study appear similar to what was reported in a June study in the New England Journal of Medicine, which found that hydroxychloroquine did not prevent illness when used within four days of being exposed. 

In July, The Food and Drug Administration (FDA) withdrew the emergency use authorization for both chloroquine and hydroxychloroquine due to serious safety issued.

Doctors have warned that the drugs can cause serious heart problems, but the FDA had previously allowed their use for hospitalized patients and during clinical trials.

Trump repeatedly promoted the drug as a potential miracle treatment for the virus. He said in May that he had been taking hydroxychloroquine, in combination with zinc, as a way to prevent getting COVID-19.

Trump’s promotion of the drug has led to shortages for people that need it for other conditions. Hydroxychloroquine, which was initially approved as an anti-malaria drug, is also used to treat lupus and rheumatoid arthritis. 

Source Article

Trump-touted hydroxychloroquine shows no benefit in COVID-19 prevention: study

(Reuters) – A malaria drug taken by U.S. President Donald Trump to prevent COVID-19 did not show any benefit versus placebo in reducing coronavirus infection among healthcare workers, according to clinical trial results published on Wednesday.

The study largely confirms results from a clinical trial in June that showed hydroxychloroquine was ineffective in preventing infection among people exposed to the new coronavirus.

Trump began backing hydroxychloroquine early in the pandemic and told reporters in May he started taking the drug after two White House staffers tested positive for COVID-19. Studies have found the drug to offer little benefit as a treatment.

In the study of 125 participants, four who had taken hydroxychloroquine as a preventative treatment for eight weeks contracted COVID-19, and four on placebo tested positive for the virus.

All eight were either asymptomatic or had mild symptoms that did not require hospitalization, according to the results published in the JAMA Internal Medicine journal.

The research shows that routine use of the drug cannot be recommended among healthcare workers to prevent COVID-19, researchers from the University of Pennsylvania said.

The study authors said it was possible that a trial conducted in a community with higher prevalence of the disease could allow detection of a greater benefit from the drug.

In the latest trial, which was terminated before it could reach its enrollment target of 200 participants, mild side effects such as diarrhea were more common in participants taking the malaria drug compared to placebo.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

Source Article

Hydroxychloroquine didn’t protect health care workers from coronavirus, study shows

Another study is warning against President Trump’s debunked coronavirus treatment.

Despite being studied as an early coronavirus treatment, studies have found the malaria drug hydroxychloroquine ineffective and even dangerous when used to fight coronavirus. A study published Wednesday added to that evidence, finding that the drug was ineffective in preventing health care workers from contracting coronavirus.

For the study published in JAMA Internal Medicine, researchers at the University of Pennsylvania focused on 125 health care workers. Some of them received hydroxychloroquine for eight weeks from April to July, while others got a placebo. Throughout that time, four of the 64 workers who got the drug ended up with COVID-19, while four of the 61 who got the placebo did as well. Six of those who tested positive developed coronavirus symptoms, but none needed to be hospitalized. As a result, the researchers said they “cannot recommend the routine use of hydroxychloroquine” to prevent infections among health care workers.

In June, a clinical trial published in the New England Journal of Medicine also showed hydroxychloroquine wasn’t effective in preventing coronavirus infections after exposure to the virus. The FDA has since removed its emergency use authorization for the drug as a coronavirus treatment, and in July it released a study showing how the drug could cause serious side effects in hospitalized patients.

More stories from theweek.com
Chris Wallace is ‘sad’
Trump pummels Biden — and America
GOP Sen. Tim Scott calls for Trump to correct his Proud Boys comments: ‘If he doesn’t correct it, I guess he didn’t misspeak’

Source Article

Trump-Touted Hydroxychloroquine Shows No Benefit in COVID-19 Prevention: Study | Top News

(Reuters) – A malaria drug taken by U.S. President Donald Trump to prevent COVID-19 did not show any benefit versus placebo in reducing coronavirus infection among healthcare workers, according to clinical trial results published on Wednesday.

The study largely confirms results from a clinical trial in June that showed hydroxychloroquine was ineffective in preventing infection among people exposed to the new coronavirus.

Trump began backing hydroxychloroquine early in the pandemic and told reporters in May he started taking the drug after two White House staffers tested positive for COVID-19. Studies have found the drug to offer little benefit as a treatment.

In the study of 125 participants, four who had taken hydroxychloroquine as a preventative treatment for eight weeks contracted COVID-19, and four on placebo tested positive for the virus.

All eight were either asymptomatic or had mild symptoms that did not require hospitalization, according to the results published in the JAMA Internal Medicine journal.

The research shows that routine use of the drug cannot be recommended among healthcare workers to prevent COVID-19, researchers from the University of Pennsylvania said.

The study authors said it was possible that a trial conducted in a community with higher prevalence of the disease could allow detection of a greater benefit from the drug.

In the latest trial, which was terminated before it could reach its enrollment target of 200 participants, mild side effects such as diarrhea were more common in participants taking the malaria drug compared to placebo.

(Reporting by Manas Mishra in Bengaluru; Editing by Shinjini Ganguli)

Copyright 2020 Thomson Reuters.

Source Article